Serum Cystatin C Predicts Stroke Clinical Outcomes at 1 Year Independent of Renal Function

Objective: Serum cystatin C (CysC) is a sensitive marker of renal function to predict cardiovascular diseases. We aimed to investigate the predictive value of CysC for clinical outcomes independent of renal function in patients with acute ischemic stroke (AIS). Methods: We measured serum CysC levels...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in neurology Vol. 12; p. 676872
Main Authors Ding, Yarong, Liu, Liping, Chen, Zimo, Li, Hao, Pan, Yuesong, Wang, Junfeng, Meng, Xia, Lin, Jinxi, Jing, Jing, Xie, Xuewei, Xiang, Xianglong, Wang, Yongjun
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 11.08.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective: Serum cystatin C (CysC) is a sensitive marker of renal function to predict cardiovascular diseases. We aimed to investigate the predictive value of CysC for clinical outcomes independent of renal function in patients with acute ischemic stroke (AIS). Methods: We measured serum CysC levels in 10,256 AIS patients from Third China National Stroke Registry (CNSR-III). The primary outcome was a combination of all-cause mortality and major disability (modified Rankin scale score, 3–6). Secondary outcomes included stroke recurrence and combined vascular events at 1 year. Outcomes were analyzed using logistic regression and Cox proportional hazards models, respectively. Results: The median CysC of included patients was 0.95 mg/l (interquartile range, 0.83–1.10 mg/l). A U-shaped association was observed between CysC and primary outcome (all-cause mortality or major disability) [quartile (Q)1 vs. Q2: adjusted odds ratio (aOR) 1.29, 95% CI 1.06–1.58, p = 0.012; Q3 vs. Q2: aOR 1.12, 95% CI 0.93–1.35, p = 0.242; Q4 vs. Q2: aOR 1.35, 95% CI 1.10–1.65, p = 0.004]. A similar trend also existed in “preserved renal function” patients. Adding CysC to a model containing conventional risk factors improved the model performance with integrated discrimination improvement (IDI) of 0.13% ( p = 0.016) and net reclassification index (NRI) of 13.10% ( p <0.001) for primary outcome. No significant association was observed for stroke recurrence or combined vascular event rate in different CysC quartiles. Conclusions: CysC showed a U-shaped correlation with 1-year stroke clinical outcome, suggesting that serum CysC may not only be a simple candidate marker of renal function.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Robert G. Kowalski, University of Colorado, United States
Reviewed by: Jijun Shi, Second Affiliated Hospital of Soochow University, China; Wi-Sun Ryu, Dongguk University Ilsan Hospital, South Korea
This article was submitted to Stroke, a section of the journal Frontiers in Neurology
ISSN:1664-2295
1664-2295
DOI:10.3389/fneur.2021.676872